Dr Meric-Bernstam on the Use of Trastuzumab Deruxtecan in HER2+ Solid Tumors


In Partnership With:

Funda Meric-Bernstam, MD, discusses the phase 2 DESTINY-PanTumor02 trial of trastuzumab deruxtecan in difficult-to-treat HER2-positive solid tumors.

Funda Meric-Bernstam, MD, chair, the Department of Investigational Cancer Therapeutics–the Phase I Program, medical director, the Institute for Personalized Cancer Therapy (IPCT), the Nellie B. Connally Chair in Breast Cancer, the University of Texas MD Anderson Cancer Center, discusses the phase 2 DESTINY-PanTumor02 trial (NCT04482309) of fam-trastuzumab deruxtecan-nxki (Enhertu) in difficult-to-treat HER2-positive solid tumors.

At the 2023 ASCO Annual Meeting, investigators presented data from the phase 2 study, specifically focusing on results from the primary end point of the trial of investigator-assessed objective response rate (ORR), Meric-Bernstam begins. Some of the secondary end points, such as duration of response (DOR) and disease control rate, were also discussed. Notably, investigators saw a response across multiple tumor types, including cervical, endometrial, ovarian, biliary tract, bladder, and other cancers, Meric-Bernstam adds.

The ORR in the total population of the 267 patients was 37.1%, including a complete response rate of 5.6%. Moreover, the overall median DOR reported was 11.8 months. In patients with cervical (n = 40), endometrial (n = 40), ovarian (n = 40), biliary tract (n = 41) pancreatic (n = 25), bladder (n = 41), and other cancers (n = 40) the ORRs were 50.0%, 57.5%, 45.0%, 22.0%, 4.0%, 39.0%, and 30.0%, respectively.

The cohort where patients experienced the least amount of activity with trastuzumab deruxtecan was pancreatic cancer, Meric-Bernstam continues. However, this was not a surprising results since pancreatic cancer is a traditionally difficult disease to treat, Meric-Bernstam says. Notably, patients in the pancreatic cancer cohort experienced a stable disease rate of 68%, Meric-Bernstam concludes.

Related Videos
Naval G. Daver, MD
Pasi A. Jänne, MD, PhD
Saad Z. Usmani, MD, MBA, FACP
J. Randolph (Randy) Hecht, MD
Alessandro Di Federico, MD
Qian (Janie) Qin, MD
Judy C. Boughey, MD
Tian Zhang, MD, MHS
Francisco J. Esteva, MD, PhD
Related Content